Discovery of synthetic leishmania inhibitors by screening of a 2-arylbenzothiophene library

Chemical Biology and Drug Design

Volumn 83, Issue 3, 2014, Pages 289-296

  Bonano, Vivian I ^a   Yokoyama Yasunaka, Jenicer K U ^a   Miguel, Danilo C ^a,c   Jones, Scott A ^b   Dodge, Jeffrey A ^b   Uliana, Silvia R B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

leishmaniasis; selective estrogen receptor modulator; tamoxifen

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; BENZOTHIOPHENE DERIVATIVE; CLOMIFENE; ESTROGEN RECEPTOR; TAMOXIFEN; TOREMIFENE;

ALKYLATION; AMASTIGOTE; ARTICLE; BIOSYNTHESIS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DEOXYGENATION; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; FRIEDEL CRAFTS REACTION; IC 50; IN VITRO STUDY; ISOMERIZATION; LEISHMANIA; LEISHMANIASIS; MOLECULAR LIBRARY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROMASTIGOTE; REDUCTION; VERO CELL; VIRUS ENTRY;

MURINAE;

LEISHMANIASIS; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; DRUG EVALUATION, PRECLINICAL; LEISHMANIA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; VERO CELLS;

EID: 84896719035     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12239     Document Type: Article

References (35)

1. den Boer M., Argaw D., Jannin J., Alvar J., (2011) Leishmaniasis impact and treatment access. Clin Microbiol Infect; 17: 1471-1477.
2. Alvar J., Vélez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M., WHO Leishmaniasis Control Team. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE; 7: e35671.
3. Murray H.W., Berman J.D., Davies C.R., Saravia N.G., (2005) Advances in leishmaniasis. Lancet; 366: 1561-1577.
4. Bern C., Maguire J.H., Alvar J., (2008) Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis; 2: e313.
5. Seifert K., Perez-Victoria F.J., Stettler M., Sanchez-Canete M.P., Castanys S., Gamarro F,., Croft S.L., (2007) Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents; 30: 229-235.
6. Machado P.R., Ampuero J., Guimaraes L.H., Villasboas L., Rocha A.T., Schriefer A., Sousa R.S., Talhari A., Penna G., Carvalho E.M., (2010) Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis; 4: e912.
7. Neves L.O., Talhari A.C., Gadelha E.P., Silva Junior R.M., Guerra J.A., Ferreira L.C., Talhari S., (2011) A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol; 86: 1092-1101.
8. Inocencio da Luz R., Romero G.A., Dorval M.E., Cruz I., Canavate C., Dujardin J.C., Van Assche T., Cos P., Maes L., (2011) Drug susceptibility of Leishmania infantum (syn. Leishmania chagasi) isolates from Brazilian HIV-positive and HIV-negative patients. J Antimicrob Chemother; 66: 677-679.
9. Rojas R., Valderrama L., Valderrama M., Varona M.X., Ouellette M., Saravia N.G., (2006) Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis; 193: 1375-1383.
10. Altan N., Chen Y., Schindler M., Simon S.M., (1999) Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc Natl Acad Sci USA; 96: 4432-4437.
11. O'Brian C.A., Liskamp R.M., Solomon D.H., Weinstein I.B., (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res; 45: 2462-2465.
12. Mandlekar S., Kong A.N., (2001) Mechanisms of tamoxifen-induced apoptosis. Apoptosis; 6: 469-477.
13. Cabot M.C., Giuliano A.E., Volner A., Han T.Y., (1996) Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett; 394: 129-131.
14. Miguel D.C., Yokoyama-Yasunaka J.K., Andreoli W.K., Mortara R.A., Uliana S.R., (2007) Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother; 60: 526-534.
15. Miguel D.C., Zauli-Nascimento R.C., Yokoyama-Yasunaka J.K.U., Katz S., Barbieri C.L., Uliana S.R.B., (2009) Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother; 63: 365-368.
16. Miguel D.C., Yokoyama-Yasunaka J.K., Uliana S.R., (2008) Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Negl Trop Dis; 2: e249.
17. Karimian E., Chagin A.S., Gjerde J., Heino T., Lien E.A., Ohlsson C., Sävendahl L., (2008) Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. J Bone Miner Res; 23: 1267-1277.
18. Kedar R.P., Bourne T.H., Powles T.J., Collins W.P., Ashley S.E., Cosgrove D.O., Campbell S., (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet; 343: 1318-1321.
19. Iqbal J., Ginsburg O.M., Wijeratne T.D., Howell A., Evans G., Sestak I., Narod S.A., (2012) Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev; 38: 318-328.
20. Shiina I., Sano Y., Nakata K., Kikuchi T., Sasaki A., Ikekita M., Hasome Y., (2007) Synthesis of the new pseudo-symmetrical tamoxifen derivatives and their anti-tumor activity. Bioorg Med Chem Lett; 17: 2421-2424.
21. Collins D.J., Hobbs J.J., Emmens C.W., (1971) Antiestrogenic and antifertility compounds 4. 1,1,2-Triarylalkan-1-ols and 1,1,2-Triarylalk-1-enes containing basic ether groups. J Med Chem; 14: 952-957.
22. Black L.J., Goode R.L., (1980) Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci; 26: 1453-1458.
23. Jones C.D., Jevnikar M.G., Pike A.J., Peters M.K., Black L.J., Thompson A.R., Falcone J.F., Clemens J.A., (1984) Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]- phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem; 27: 1057-1066.
24. Olah G.H., (1963) Friedel-Crafts and Related Reactions, Vol. 1. General Aspects. New York: Wiley; p. 91-115.
25. Dodge J.A., Stocksdale M.G., Fahey K.J., Jones C.D., (1995) Regioselectivity in the alkaline thiolate deprotection of aryl methyl ethers. J Org Chem; 60: 739-741.
26. Schmid C.R., Sluka J.P., Duke K.M., (1999) Nucleophilic aromatic substitution on 3-aroyl-2-arylbenzothiophenes. Rapid access to raloxifene and other selective estrogen receptor modulators. Tetrahedron Lett; 40: 675-678.
27. Sall D.J., Bastian J.A., Briggs S.L., Buben J.A., Chirgadze N.Y., Clawson D.K., Denney M.L., et al,. (1997) Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure-activity relationships, and binding orientation. J Med Chem; 40: 3489-3493.
28. Sall D.J., Bailey D.L., Bastian J.A., Buben J.A., Chirgadze N.Y., Clemens-Smith A.C., Denney M.L., et al,. (2000) Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy, and pharmacokinetic properties of modified C-3 side chain derivatives. J Med Chem; 43: 649-663.
29. Zauli-Nascimento R.C., Miguel D.C., Yokoyama-Yasunaka J.K., Pereira L.I., Pelli de Oliveira M.A., Ribeiro-Dias F., Dorta M.L., Uliana S.R., (2010) In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B. Trop Med Int Health; 15: 68-76.
30. Harper M.J., Walpole A.L., (1966) Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature; 212: 87.
31. Jordan V.C., Haldemann B., Allen K.E., (1981) Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology; 108: 1353-1361.
32. Katzenellenbogen B.S., Norman M.J., Eckert R.L., Peltz S.W., Mangel W.F., (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res; 44: 112-119.
33. Grese T.A., Cho S., Finley D.R., Godfrey A.G., Jones C.D., Lugar C.W. III, Martin J., et al,. (1997) Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem; 40: 146-167.
34. Grese T.A., Pennington L.D., Sluka J.P., Adrian M.D., Cole H.W., Fuson T.R., Magee D.E., et al,. (1998) Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem; 41: 1272-1283.
35. Johansen L.M., Brannan J.M., Delos S.E., Shoemaker C.J., Stossel A., Lear C., Hoffstrom B.G., Dewald L.E., Schornberg K.L., Scully C., Lehár J., Hensley L.E., White J.M., Olinger G.G., (2013) FDA-approved selective estrogen receptor modulators inhibit ebola virus infection. Sci Transl Med; 5:190ra79.